Last reviewed · How we verify
Placebo-liraglutide
This is a placebo control formulation used in clinical trials to compare against liraglutide's active GLP-1 receptor agonist effects.
At a glance
| Generic name | Placebo-liraglutide |
|---|---|
| Also known as | Isotonic saline |
| Sponsor | University of Aarhus |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo-liraglutide refers to an inert comparator arm in clinical studies of liraglutide, the active GLP-1 receptor agonist. It contains no pharmacologically active ingredient and serves as a control to isolate the true therapeutic effects of liraglutide from placebo response. This is a research tool rather than a therapeutic agent.
Approved indications
Common side effects
Key clinical trials
- Effects of GH and Lirglutide on AgRP (PHASE4)
- SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity (PHASE3)
- A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis (PHASE2)
- The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes (PHASE2)
- Liraglutide Effects on Epicardial Fat Inflammatory Genes (PHASE4)
- Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee (PHASE1)
- Saxenda: Underlying Mechanisms and Clinical Outcomes (PHASE4)
- Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo-liraglutide CI brief — competitive landscape report
- Placebo-liraglutide updates RSS · CI watch RSS
- University of Aarhus portfolio CI